Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>

13 Jan 2007

Abstract excerpt

API-1252 (Fig. [1][1]), an inhibitor of bacterial enoyl-acyl carrier protein (enoyl-ACP) reductase (FabI), is being developed by Affinium Pharmaceuticals, Inc. (Toronto, Canada), in both oral and intravenous formulations, for single-agent and combination treatment of antimicrobial-susceptible and -

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial agents and applications
Share to Antimicrobial Resistance in Staphylococcus
Share to Bacterial biofilms and quorum sensing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17220418
DOI: 10.1128/aac.01254-06

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>PMID 17220418Read ↗

<i>In Vitro</i> Activities of Arylomycin Natural-Product Antibiotics against <i>Staphylococcus epidermidis</i> and Other Coagulase-Negative StaphylococciSemantic proximity Read ↗

In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in KoreaSemantic proximity Read ↗

Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.Semantic proximity Read ↗

Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.Semantic proximity Read ↗

In Vivo Pharmacodynamic Activity of the Glycopeptide DalbavancinSemantic proximity Read ↗

The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.Semantic proximity Read ↗

RT-PCR and Statistical Analyses of <i>adeABC</i> Expression in Clinical Isolates of <i>Acinetobacter calcoaceticus–Acinetobacter baumannii</i> ComplexSemantic proximity Read ↗

<i>In Vitro</i> Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.